FindTrial
Sign In

MD1003

DRUG5 trials

Sponsors

MedDay Pharmaceuticals SA

Conditions

ALSAmyotrophic Lateral SclerosisAnti-MAG NeuropathyCharcot-Marie-Tooth DiseaseCharcot-Marie-Tooth Disease Type 1ACharcot-Marie-Tooth Disease, Type 1BChronic Inflammatory Demyelinating PolyneuropathyHealthy Volunteers

Phase 1

TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects
NCT04168723
MedDay Pharmaceuticals SAHealthy Volunteers
Start: 2019-11-11End: 2020-03-05Target: 64Updated: 2020-02-20
RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects
TerminatedNCT04252430
MedDay Pharmaceuticals SAHealthy Volunteers, Impaired Renal Function
Start: 2019-10-09End: 2020-03-17Updated: 2020-05-13
HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects
TerminatedNCT04252417
MedDay Pharmaceuticals SAHealthy Volunteers, Hepatic Impairment of Moderate Child Pugh Category
Start: 2019-10-11End: 2020-03-17Updated: 2020-05-13

Phase 2

SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
CompletedNCT02967679
MedDay Pharmaceuticals SAAnti-MAG Neuropathy, Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth Disease Type 1A +3
Start: 2016-12-05End: 2019-03-18Updated: 2020-11-02
Effect of MD1003 in Amyotrophic Lateral Sclerosis
CompletedNCT03114215
MedDay Pharmaceuticals SAALS, Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Start: 2016-06-29End: 2017-12-31Updated: 2019-06-04

Related Papers

High-dose pharmaceutical-grade biotin in patients with demyelinating neuropathies: a phase 2b open label, uncontrolled, pilot study.
2023-10-304 citations
High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study.
2020-01-277 citations